• Figma on various competition matters, including the proposed USD20bn acquisition by Adobe through securing antitrust approvals in the US, UK, EU, and other foreign jurisdictions.*
• Maze on competition matters related to the proposed acquisition of an exclusive license by Sanofi, which included an in-depth investigation by the US FTC.*
• Sema4 on various competition matters, including its acquisition of GeneDX.*
• A public technology company on competition considerations for R&D partnerships and IP licensing agreements in the US, Europe, and Asia.*
• A large NFT exchange on competition considerations related to standard setting with competitors on royalty policies.*
• A public cloud provider on various competition matters relating to risk associated with competitor and industry agreements.*
• Databricks on competition aspects of its USD1bn acquisition of Tabular.*
• Shockwave Medical on competition aspects related to the USD13bn acquisition by JNJ.*
• Cisco Systems on competition aspects for various transactions, including securing unconditional antirust approvals in the US, Germany, Austria, and the UK for its acquisition of Isovalent.*
• Embracer on the acquisition of Gearbox by Take-Two, including securing unconditional antitrust clearances in the US and Turkey.*
• A public pharmaceutical company on competition considerations related to its authorized generic agreements.*
• A private technology company as a third party involved in the FTC's monopolization suit against Meta.*
• Wiz on various competition considerations related to certain investments.*
• AstraZenea on global merger control aspects of its USD40bn acquisition of Alexion, which included securing unconditional clearances in more than 20 antitrust and FDI jurisdictions.*
• Verizon on its USD5bn sale of Verizon Media Group to Apollo.*

*includes prior firm experience.